PrecisemAb Biotech CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Our Universal Antibody Lock™ is an innovative proprietary platform designed to generate conditionally-activated antibody therapeutics for various antibody formats, including monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. This technology enhances antibody selectivity while reducing on-target toxicity, providing safer and more effective treatment solutions for patients.
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90663465
Status
Active
Number of Employees
0
Total Paid-in
Capital
69,100,000 (NT$)
Location of Company
Taiwan
, Taipei City
Overseas Development
Japan、Korea, Republic of
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PrecisemAb Biotech develops safer antibody therapeutics using its patented Antibody Lock™ platform, enabling tumor microenvironment–specific activation to reduce systemic toxicity. Protected in 18 countries and licensed to GlycoNex in 2024, the platform is expanding into bispecifics and ADCs, with proprietary asset PSM101 targeting IND submission in 2027.
The content above was translated by Ai
